Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
16. Januar 2024 07:00 ET
|
Allakos Inc.
– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast...
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
13. November 2023 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Appoints Neil Graham to its Board of Directors
30. August 2023 16:05 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
09. August 2023 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
02. August 2023 16:05 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
12. Juni 2023 07:02 ET
|
Allakos Inc.
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated...
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
05. Juni 2023 07:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
09. Mai 2023 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
06. März 2023 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
29. November 2022 07:02 ET
|
Allakos Inc.
– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent...